Trade Idea: Short Henlius Upon Lock-Up Expiry & 2H Results, HLX01 Likely Underperformed
Shanghai Henlius Biotech (2696 HK) IPO lock-up will expire on 25th of March, six months post its listing. The stock has been underwater since...
357 Views
Henlius (复宏汉霖) Post-IPO Trading: Weak Demands Ahead of Debut, Downside Remains
Shanghai Henlius' IPO was priced at the low end and started trading today. We have highlighted in our earlier note that the IPO is over-valued with...
509 Views
HK Short Interest - Diverging Healthcare
We analyse the latest SFC data released Friday evening on short position reporting in Hong Kong for the week ended 6 September.Total short notional...
409 Views
Shanghai Henlius (复宏汉霖) IPO: Newsflow on HLX10 Clinical Trial and ASEAN Commercialization
Shanghai Fosun Pharmaceutical (Group) (2196 HK), the parent company of Shanghai Henlius which in the process of book building today to raise up to...
585 Views
Shanghai Henlius Biotech IPO: Valuation Prescribed at Low-End
Shanghai Henlius Biotech (2696 HK) is a biopharmaceutical company and a non-wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group) (2196...
526 Views